Drug General Information (ID: DDI3LCVIRU)
Drug Name			Orlistat		Drug Info		Anisindione		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiobesity Agents				Anticoagulants
Structure

Mechanism of Orlistat-Anisindione Interaction (Severity Level: Moderate)
Altered absorption (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Orlistat				Anisindione
Mechanism		Orlistat				Absorption possibly altered by orlistat
Key Mechanism Factor 1
		Factor Name		Pharmacokinetic
		Factor Description		Alters the absorption of the drug, leading to changes in the plasma concentration of the drug and affecting the pharmacological effects.
Mechanism Description		Altered absorption of Anisindione caused by Orlistat

Recommended Action
Management		Patients should be closely monitored during concomitant therapy with oral anticoagulants and orlistat. The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of orlistat in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.

References
1	MacWalter RS, Fraser HW, Armstrong KM "Orlistat enhances warfarin effect." Ann Pharmacother 37 (2003): 510-2. [PMID: 12659605]
2	Product Information. Xenical (orlistat). Roche Laboratories, Nutley, NJ.